1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Pain, Intractable in 1 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Fukumoto, Y | 1 |
| Matoba, T | 1 |
| Shiose, A | 1 |
| Nishida, T | 1 |
| Masuda, M | 1 |
| Morita, S | 1 |
| Shimokawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Pain, Intractable
| Article | Year |
|---|---|
Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Coronary Artery Bypass; Coronary Vasospasm; Dil | 2004 |